Boston, MA 09/23/2014 (wallstreetpr) – AbbVie Inc (NYSE:ABBV) announced that will be presenting findings from new researches at the annual meeting of the European Society of Medical Oncology. As mentioned in the PR Newswire article, the conference will be held from Sept 26 through Sept 30, 2014 in Madrid, Spain.
AbbVie Inc (NYSE:ABBV) has been engaged with several new clinical researches which evaluate likely new medicines and drugs. The company has several drugs lined-up in its oncology department and seeks to present the results of these studies this month.
Latest Findings
Among the various study results AbbVie Inc (NYSE:ABBV) seeks to present is a Phase II study finding. The research evaluates the safety and efficiency of veliparib in combination with two widely-acting chemotherapeutic drugs. Veliparib is essentially a poly polymerase (adenosine diphosphate [ADP]–ribose) inhibitor and the combination therapy aims at treating a particular form of cancer. The study analyses the efficacy of the treatment in patients suffering from non-small cell lung cancer.
Veliparib, or ABT-888 is also being evaluated for multiple other tumor types. PARP, a natural bodily enzyme repairs DNA damages and is sometimes responsible for repairing damaged cancer cells as well. Veliparib seeks to prevent this cancer cells repair so as to assist the efficacy of DNA destroying cancer therapies.
New Researches
AbbVie Inc (NYSE:ABBV) also seeks to make an oral presentation of the results from a Phase I study of drug ABT-414. It is an inhibitor of the epidermal growth factor receptor (anti-EGFR) monoclonal antibody conjugation drug therapy. The treatment targets patients who are newly diagnosed with glioblastoma multiforme (GBM), a kind of brain tumor. GBM is the most commonly found and also the most aggressive form of cancerous primary brain tumor.
Apart from this, the drug maker will be presenting a study named ABT-767, which concerns advance-stage solid tumors. The therapy seeks to treat tumors with BRCA 1 and BRCA 2 mutations, as well as high-level Serous Ovarian or Fallopian Tube and Primary Peritoneal Cancer.
